Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.65 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | SMO | Q99835 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078109 | 0.89 | RORC (0.70) | RORCKCNJ11RAB9AGRM4KCNK3 | |
| SCHEMBL31078090 | 0.85 | RORC (0.61) | RORCKCNJ11TP53MEN1KMT2A | |
| SCHEMBL3455263 | 0.80 | CYP1A2 (0.70) | TP53MEN1KMT2ANPC1RAB9A | |
| SCHEMBL31078114 | 0.79 | RORC (1.00) | RORCKCNJ11MEN1KMT2ANPC1 | |
| SCHEMBL12334368 | 0.79 | RORC (1.00) | RORCKCNJ11MEN1KMT2ANPC1 | |
| SCHEMBL2261736 | 0.77 | KCNK3 (0.60) | RORCKCNJ11TP53MEN1KMT2A | |
| SCHEMBL31078161 | 0.77 | RORC (0.67) | RORCKCNJ11TP53MEN1KMT2A | |
| SCHEMBL13852809 | 0.76 | CFTR (0.58) | RORCTP53KMT2ANPC1RAB9A | |
| SCHEMBL7114931 | 0.74 | KCNJ11 (1.00) | KCNJ11 | |
| SCHEMBL18804918 | 0.73 | GRM4 (0.63) | MEN1KMT2ARAB9AGRM4RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245633-A1 | ROR Gamma Agonists as Enhancers of Protective Immunity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245633-A1 | ROR Gamma Agonists as Enhancers of Protective Immunity | RORC, RORB, RORA | RORC 1/4885KCNJ11 4734/4885TP53 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.